moron. preferred stock is convertible to common stock, the pps will not go down when these rights are exercised.
there is no doubt. they are heading for compliance ($4) then it's a wild guess as to when the warrants are executed and for what profit, but I assume it will be a blip in the sea of noise even then.
I still see $20 as my exit target, but won't refrain from selling half at $10. I am 43 years old, but more than comfortable with $200k profit on this investment wich I had all but written off.
beer. beer :) moving to a national listing, well, so they know $4 nasdaq min bid is in the cards soon. I have an awful dca above $3, but hey. $4 migt as ewll mean $40 if the science works. and dirk haussecker says it does...
As you all know, I'm holding on until at least $4. No point in selling. But see Dirk Haussecker's post today in RNAITherapeutics. CRN bette then Antisense. How much is ISIS mktcap now?
"Recently at the 55th Annual Meeting of the American Society for Hematology in New Orleans, ProNAi presented safety and efficacy data from its ongoing Phase II study. ProNAi presented data demonstrating that PNT2258, their first-in-class BCL2 targeted drug, exhibited single agent anti-tumor activity in patients with recurrent or refractory Non-Hodgkin's Lymphoma. Further, PNT2258 is safe at a dose of 120 mg/m2 IV administered for 2-3 hours on days 1-5 of a 21-day schedule. No tumor lysis syndrome or major organ toxicities were observed. No occurrences of elevated liver enzymes, hyperkalemia, hyperphosphatemia, hypocalcemia, renal failure/dysfunction, or infections were noted."
Marina Biotech Monetizes UNA Intellectual Property Estate ThroughAgreement With Arcturus Therapeutics
CAMBRIDGE, MA, Aug 14, 2013 (Menafn - Marketwired via COMTEX) --Marina Biotech, Inc. (pinksheets:MRNA)
--Assigns Unlocked Nucleobase Analog (UNA) patents to Arcturus but
retains non-exclusive rights
--Announces the issuance and allowance of several patents which
represent significant advances in the delivery of nucleic acid-based
therapeutics including: amino acid containing liposomal formulations,
delivery of messenger RNA compounds, and subcutaneous administration
--Provides update on financial situation and relocation to Cambridge, MA
And so on.